Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
SESEN BIO INC (SESN) Stock Price & Overview
NASDAQ:SESN • US8177631053
Current stock price
0.6288 USD
+0.04 (+7.29%)
At close:
0.5832 USD
-0.05 (-7.25%)
After Hours:
The current stock price of SESN is 0.6288 USD. Today SESN is up by 7.29%. In the past month the price increased by 8.32%. In the past year, price increased by 0.5%.
SESN Key Statistics
52-Week Range0.365 - 0.965
Current SESN stock price positioned within its 52-week range.
1-Month Range0.525 - 0.6449
Current SESN stock price positioned within its 1-month range.
- Market Cap
- 127.956M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.16
- Dividend Yield
- N/A
SESN Stock Performance
Today
+7.29%
1 Week
+8.41%
1 Month
+8.32%
3 Months
+18.64%
Longer-term
6 Months -3.71%
1 Year +0.50%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
SESN Stock Chart
SESN Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to SESN. When comparing the yearly performance of all stocks, SESN is one of the better performing stocks in the market, outperforming 90% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
SESN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SESN. The financial health of SESN is average, but there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
SESN Earnings
Next Earnings DateMay 8, 2023
Last Earnings DateFeb 28, 2023
PeriodQ4 / 2022
EPS Reported-$0.80
Revenue Reported
EPS Surprise 64.35%
Revenue Surprise %
SESN Forecast & Estimates
6 analysts have analysed SESN and the average price target is 12.24 USD. This implies a price increase of 1846.56% is expected in the next year compared to the current price of 0.6288.
For the next year, analysts expect an EPS growth of -308% and a revenue growth -100% for SESN
Analysts
Analysts43.33
Price Target12.24 (1846.56%)
EPS Next Y-308%
Revenue Next Year-100%
SESN Financial Highlights
Over the last trailing twelve months SESN reported a non-GAAP Earnings per Share(EPS) of -1.16. The EPS decreased by -364% compared to the year before.
Income Statements
Revenue(TTM)60.00M
Net Income(TTM)-4.17M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%455.56%
Sales Q2Q%N/A
EPS 1Y (TTM)-364%
Revenue 1Y (TTM)816.87%
SESN Ownership
Ownership
Inst OwnersN/A
Shares203.49M
Float183.80M
Ins Owners1.16%
Short Float %N/A
Short RatioN/A
SESN Industry Overview
SESN operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
50%
Outperformed 50% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.1%
- New Lows
- 4.6%
- Average ROE
- 48.5%
- Average Profit Margin
- 20.5%
- Average Operating Margin
- 33.6%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.2
SESN Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 373.774B | ||
| AMGN | AMGEN INC | 13.88 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.44 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.042B | ||
| INCY | INCYTE CORP | 10.61 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SESN
Company Profile
Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 35 full-time employees. The company went IPO on 2014-02-06. The firm's product candidates are based on its TFPT platform and are focused on addressing areas of unmet medical need in cancer. TFPTs are single protein therapeutics composed of targeting domains genetically fused via peptide linkers to cytotoxic protein payloads that are produced through its recombinant one-step, microbial manufacturing process. The Company’s advanced product candidate Vicinium, also known as VB4-845, which is composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of bacillus calmette-guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC).
Company Info
IPO: 2014-02-06
SESEN BIO INC
245 1st St Ste 1800
Cambridge MASSACHUSETTS 02142 US
CEO: Thomas R. Cannell
Employees: 35
Phone: 16174448550.0
SESEN BIO INC / SESN FAQ
Can you describe the business of SESEN BIO INC?
Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 35 full-time employees. The company went IPO on 2014-02-06. The firm's product candidates are based on its TFPT platform and are focused on addressing areas of unmet medical need in cancer. TFPTs are single protein therapeutics composed of targeting domains genetically fused via peptide linkers to cytotoxic protein payloads that are produced through its recombinant one-step, microbial manufacturing process. The Company’s advanced product candidate Vicinium, also known as VB4-845, which is composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of bacillus calmette-guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC).
What is the current price of SESN stock?
The current stock price of SESN is 0.6288 USD. The price increased by 7.29% in the last trading session.
What is the dividend status of SESEN BIO INC?
SESN does not pay a dividend.
How is the ChartMill rating for SESEN BIO INC?
SESN has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists SESN stock?
SESN stock is listed on the Nasdaq exchange.
Who owns SESEN BIO INC?
You can find the ownership structure of SESEN BIO INC (SESN) on the Ownership tab.